首页> 外文期刊>Human Genetics >Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma
【24h】

Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma

机译:通过分析6p22.3、12p13.33-12.1、17q22-23.2和18q23 SNP基因型在家族性和非家族性神经胶质瘤中的易感性

获取原文
获取原文并翻译 | 示例
       

摘要

The risk of glioma has consistently been shown to be increased twofold in relatives of patients with primary brain tumors (PBT). A recent genome-wide linkage study of glioma families provided evidence for a disease locus on 17q12-21.32, with the possibility of four additional risk loci at 6p22.3, 12p13.33-12.1, 17q22-23.2, and 18q23. To identify the underlying genetic variants responsible for the linkage signals, we compared the genotype frequencies of 5,122 SNPs mapping to these five regions in 88 glioma cases with and 1,100 cases without a family history of PBT (discovery study). An additional series of 84 familial and 903 non-familial cases were used to replicate associations. In the discovery study, 12 SNPs showed significant associations with family history of PBT (P 0.001). In the replication study, two of the 12 SNPs were confirmed: 12p13.33-12.1 PRMT8 rs17780102 (P = 0.031) and 17q12-21.32 SPOP rs650461 (P = 0.025). In the combined analysis of discovery and replication studies, the strongest associations were attained at four SNPs: 12p13.33-12.1 PRMT8 rs17780102 (P = 0.0001), SOX5 rs7305773 (P = 0.0001) and STKY1 rs2418087 (P = 0.0003), and 17q12-21.32 SPOP rs6504618 (P = 0.0006). Further, a significant gene-dosage effect was found for increased risk of family history of PBT with these four SNPs in the combined data set (P trend 1.0 × 10−8). The results support the linkage finding that some loci in the 12p13.33-12.1 and 17q12-q21.32 may contribute to gliomagenesis and suggest potential target genes underscoring linkage signals.
机译:胶质瘤的风险一直被证明在患有原发性脑肿瘤(PBT)患者的亲属中增加了两倍。最近一项对神经胶质瘤家族的全基因组连锁研究为17q12-21.32上的疾病基因座提供了证据,并可能在6p22.3、12p13.33-12.1、17q22-23.2和18q23处有四个额外的风险基因座。为了确定负责连锁信号的潜在遗传变异,我们比较了88个神经胶质瘤病例和1,100个没有PBT家族史的神经胶质瘤病例中映射到这五个区域的5,122个SNP的基因型频率(发现研究)。另外的84个家族和903个非家族病例系列被用于复制关联。在发现研究中,有12个SNPs与PBT家族史显着相关(P <0.001)。在复制研究中,确认了12个SNP中的两个:12p13.33-12.1 PRMT8 rs17780102(P = 0.031)和17q12-21.32 SPOP rs650461(P = 0.025)。在发现和复制研究的组合分析中,在四个SNP处获得了最强的关联:12p13.33-12.1 PRMT8 rs17780102(P = 0.0001),SOX5 rs7305773(P = 0.0001)和STKY1 rs2418087(P = 0.0003)和17q12 -21.32 SPOP rs6504618(P = 0.0006)。此外,在组合数据集中发现这四个SNP的PBT家族史风险增加的显着基因剂量效应(P趋势 <1.0×10-8 )。结果支持了连锁发现,即12p13.33-12.1和17q12-q21.32中的某些基因座可能有助于神经胶质瘤的发生,并暗示了潜在的靶基因突显了连锁信号。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号